Presentation

Intervacc develop new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care, with a very good safety profile. Now, after many years of research, we are in the final development stage of Strangvac, a modern equine strangles vaccine. The Company’s Marketing Authorization Application (MAA) for review of Strangvac has recently been submitted to the European Medicines Agency (EMA).